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(ILD) experience a high-risk of treatment-related morbidity and 
mortality after any pulmonary radiotherapy. The purpose of this 
study is to systematically review existing literature on SABR-
related mortality and ILD-specific toxicity for patients with co-
existing ES-NSCLC and ILD. 
Methods and Materials: The MEDLINE and Embase databases 
were queried from their respective dates of inception to January 
21, 2016. A total of 3101 records were reviewed. Studies 
involving advanced stage NSCLC, non-SABR radiotherapy 
technique, guidelines, reviews, meta-analyses, 
correspondences, or pediatric populations were excluded. SABR-
related mortality was defined as any death secondary to 
radiation pneumonitis or deaths determined to be directly 
related to radiation therapy by individual study investigators. 
Treatment-related ILD-specific toxicity was defined as Grade ≥ 3 
radiation pneumonitis following SABR. Data on treatment-
related mortality and ILD-specific toxicity for surgical studies 
were also extracted for reference. Mortality and morbidity 
results were summarized with weighted means. 
Results: A total of 13 SABR studies published between 2003 and 
2015 were included in this systematic review. Ten studies were 
retrospective in design, with the others being a mixed 
retrospective/prospective observational study, a Phase I clinical 
trial and a case report. A total of 122 patients were included in 
the reports, with most studies including medically inoperable 
patients. Weighted mean for treatment-related mortality was 
15.6% after SABR in patients with co-existing ES-NSCLC and ILD. 
Treatment-related ILD-specific toxicity occurred in 25.9% of 
SABR patients. An additional 28 surgical studies were reviewed, 
which included a total of 1681 patients. From 1999 to 2015, 
medically operable patients with co-existing ES-NSCLC and ILD 
who underwent surgery experienced treatment-related mortality 
of 2.0% and ILD-specific toxicity of 11.7%. 
Conclusions: A high incidence of treatment-related mortality 
(16%) and ILD-specific toxicity (26%) was observed after SABR for 
patients with co-existing ES-NSCLC and ILD. Many SABR patients 
were medically inoperable, preventing direct comparisons with 
surgical outcomes. Patients should be cautioned about this 
increased risk of toxicity. Future studies should aim to establish 
a specific diagnosis of the type and severity of ILD prior to the 
treatment of any patient with ES-NSCLC and co-existing 
pulmonary comorbidity. 
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Purpose: Sarcopenia, a depletion of a skeletal muscle with or 
without loss of fat mass, has been studied as a prognostic factor 
in several cancers. It has been shown to be associated with 
poorer survival and worse post-operative outcomes independent 
of patients' body weight. However, it has not been used in 
routine clinical evaluation nor has its prognostic significance in 
lung cancer been evaluated. This study examined the value of 
sarcopenia as a prognostic factor in patients with locally 
advanced non-small cell lung cancers treated with radical 
radiation and chemotherapy.  
Methods and Materials: This study included all patients with 
Stage III non-small cell lung cancer treated with radical radiation 
and chemotherapy at a regional cancer centre using the Glans 
Look database between 2006 and 2012. Body composition 
analysis of planning or pre-treatment diagnostic CT scans was 
performed using Eclipse (Varian, Palo Alto, CA) per a previously 
validated and reported technique. Total skeletal muscle area 
was calculated on a single axial abdominal CT slice at the level 
of L3 vertebral body and adjusted for stature. Patients were 
classified as sarcopenic or nonsarcopenic using validated sex-
specific cut-offs of L3 skeletal muscle index (52.4 cm2/m2 for 
males and 38.5 cm2/m2 for females). Kaplan-Meier survival 
estimates and Cox proportional-hazard models were used to 
determine the impact of sarcopenia on overall survival. 
Results: A total of 106 patients (53% males, 47% females), with 
mean age 65 years (SD = 8.7) were analyzed. Mean BMI was 26.3 
kg/m2 (SD = 6.7 kg/m2). Only one patient was underweight (BMI 
< 18.5), 40% patients had normal weight and 60% of patients were 
either overweight or obese. Overall, 38.7% patients were 
sarcopenic. The prevalence of sarcopenia was 56% among 
patients with normal weight and 27% among overweight or obese 
patients. Sarcopenia was identified as an independent predictor 
of overall survival on multivariate analysis (hazard ratio 1.71; 
95% CI 1.09 – 2.72, p = 0.019). Other significant predictors for 
worse overall survival included age over 65 years and absence of 
concurrent chemotherapy. Median survival in sarcopenic patients 
was 21 months (95% CI 13 – 28 months) compared with 31 months 
(95% CI 20 – 39 months) in nonsarcopenic patients.  
Conclusions: Sarcopenia is independently associated with 
inferior survival in patients with locally advanced non-small cell 
lung cancers treated with chemoradiotherapy. It can be routinely 
assessed in clinical practice using radiation planning software. 
Sarcopenia as independent predictor for survival and toxicity 
outcomes should be included in larger prospective clinical 
studies.  
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Purpose: The management of small cell lung cancer (SCLC) with 
radiotherapy (RT) is variable, with many treatment regimens 
described in the literature. We created a survey to assess 
patterns of practice and clinical decision making in the 
management of SCLC by Canadian radiation oncologists (ROs).  
Methods and Materials: A 35-item survey was e-mailed to 
Canadian ROs. Questions investigated the role of RT, dose/timing 
of RT, target delineation, and use of prophylactic cranial 
irradiation (PCI) in limited stage (LS) and extensive stage (ES) 
SCLC.  
Results: Fifty-two eligible ROs responded. For LS-SCLC, staging 
(98%) and simulation/dosimetric (96%) CT imaging were key 
determinants of RT suitability. The two most common 
dose/fractionation schedules were 40-45 Gy/15 once daily (QD) 
(40%) and 45 Gy/30 twice daily (33%). Elective nodal irradiation 
was performed by 31% of ROs. Preferred management of clinical 
T1/2aN0 SCLC favored primary chemoradiotherapy (64%). For ES-
SCLC, consolidative thoracic RT was frequently offered (88%), 
with a preferred dose/fractionation of 30 Gy/10 QD (70%). 
Twenty-three ROs (44%) would not offer extrathoracic 
consolidative RT. After response to initial treatment, PCI was 
generally offered in both LS- (100%) and ES- (98%) SCLC. 
Performance status, baseline cognition, and pre-PCI brain 
imaging were important clinical factors assessed prior to offering 
PCI.  
Conclusions:  There are both variations and alignment in 
practice in the management of SCLC by Canadian ROs. Future 
clinical trials and national treatment guidelines may reduce 
variability in treating early-stage disease, optimizing 
dose/targeting in LS-SCLC, and defining suitability for both PCI 
and consolidative RT. 
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Purpose: Prophylactic cranial irradiation (PCI) has been shown 
to provide a survival benefit and decrease occurrence of brain 
metastases in patients with small cell lung cancer (SCLC). 
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Detriment to cognitive function is suggested by some studies, but 
whether this risk changes based on age is unknown. The purpose 
of this project was to determine patterns of practice of PCI for 
both limited stage SCLC (LS-SCLC) and extensive stage SCLC (ES-
SCLC) across Canada with a focus on how age affects 
recommendations in clinical practice. 
Methods and Materials: A survey was created in English and 
French. It was approved and distributed through Canadian 
Association of Radiation Oncology (CARO) to all its radiation 
oncologist members. Answers were collected anonymously using 
Google Forms over a five week period. Descriptive statistics were 
used to analyze responses. 
Results: Fifty-seven responses were collected with 
representation from all CARO regions. Ninety-eight percent of 
respondents routinely would recommend PCI for LS-SCLC and 78% 
for ES-SCLC. For LS-SCLC, age was an independent factor for 
recommending PCI for 52% of respondents, and 65% used an age 
cut off of 80 – 84 years. For ES-SCLC, only 46% of respondents 
would consider age when recommending PCI, and 48% of those 
also used 80 – 84 years as the cut off. 85% justified this cut point 
based on poor patient outcome in their own or a colleague’s 
experience. Forty-two percent of respondents who didn't use an 
age cut off indicated that a patient's performance status was a 
more relevant criterion. 
Conclusions: Based on the consensus opinion from this survey, 
we would suggest PCI for SCLC should be offered to patients with 
acceptable performance status under 80 years of age. For 
patients 80 years and older, caution is recommended. 
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Purpose: The current standard of care for unresectable locally 
advanced Stage III non-small cell lung cancer (NSCLC) is 
chemoradiotherapy. However, there is no established consensus 
for the optimal chemotherapy regimen. We designed a Phase I 
study of docetaxel and cisplatin (DC) chemotherapy with 
concurrent thoracic radiotherapy (RT) followed by consolidative 
DC for locally advanced NSCLC. The primary objective of this 
study is to determine optimal concurrent and consolidative DC 
doses, with secondary objectives to describe associated 
toxicities. 
Methods and Materials:  Patients with histologically or 
cytologically proven and unresectable Stage IIIA or IIIB (dry) 
NSCLC were eligible for this single-institution research-ethics 
board approved study. In the concurrent cycles with thoracic RT, 
C was given every three weeks (fixed at 75mg/m2) and D given 
weekly. The starting dose of D was 20 mg/m2 weekly escalated 
in cohorts of three to define the maximum tolerated dose. RT 
was prescribed to a dose of 60 Gy in 30 fractions. This was 
followed by two cycles of consolidative DC, which were dose 
escalated if concurrent chemoradiotherapy was tolerated. 
Evaluation for dose limiting toxicities was performed on a weekly 
basis during RT. Tumour response was characterized through the 
RECIST criteria. Actuarial outcomes of overall survival (OS) and 
progression-free survival (PFS) were estimated using Kaplan-
Meier analysis. 
Results:  Between September 2004 to June 2014, 26 patients 
were enrolled. One patient did not receive protocol-specified 
treatment due to metastatic disease on baseline imaging. Of the 
eligible patients, 18 had Stage IIIA and seven had Stage IIIB 
disease. The median OS all patients was 33.6 months (95% CI 
15.8-71.6). Median PFS was 17.0 months (95% CI 9.2-26.3) with 
median follow up of 26.6 months (range 0.43 -110.8). The 
majority of patients (19/26) completed both phases of treatment 
and most received concurrent D at 20mg/m2 weekly. Eight 
patients tolerated dose escalation of posterior consolidative C or 
D. Twelve patients experienced Grade 3 toxicities (five 
esophagitis, one pneumonitis, three nausea, one leukopenia, and 
two neutropenia). Three patients had Grade 4 neutropenia. No 
patients died due to early or late treatment toxicities. Complete 
response, partial response, and stable disease were observed in 
one, 16 and four patients, respectively. Five patients underwent 
surgical resection, and three of five did not have evidence of 
residual disease. 
Conclusions:  Cisplatin and docetaxel (DC) chemotherapy with 
concurrent radiation treatment followed by consolidative DC 
achieved promising results in the treatment of Stage III NSCLC in 
light of reported outcomes from RTOG 0617 (standard arm 
median PFS 11.8, OS 28.7 months). However, treatment 
toxicities should be considered. The dose finding results of this 
study will inform the design of Phase II/III trials. 
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Purpose: Cutaneous squamous cell carcinoma (cuSCC) accounts 
for approximately 30% of all skin cancers and is one of the most 
common cancers in North America. The standard treatment for 
locally advanced cuSCC is surgery followed by adjuvant 
radiotherapy (RT). Patients presenting with locally advanced or 
recurrent disease are often elderly or immunosuppressed, and 
may be medically inoperable or technically unresectable. These 
patients are traditionally treated with radiotherapy alone since 
adding concurrent chemotherapy may not be well tolerated by 
this group. The risk of locoregional recurrence is about 40% for 
RT alone, compared to 15% in those treated by surgery and RT. 
Cetuximab is an antagonistic monoclonal chimeric IgG1 antibody 
that binds to the epidermal growth factor receptor (EGFR). EGFR 
overexpression in cuSCC varies between 43–100% of patients. 
Small, single institutional studies have retrospectively reported 
synergistic activity when combining Cetuximab and RT (CRT) for 
the treatment of metastatic or unresectable cuSCC. In 
preparation for a larger Phase II study, this project prospectively 
identified patients with unresectable cuSCC who were 
candidates for CRT. 
Methods and Materials: Three patients have been treated with 
CRT in the last 18 months. Data regarding patient outcome and 
tolerability was collected prospectively. Cetuximab was 
delivered weekly, with the first dose timed as a loading dose (400 
mg/m2) seven days prior to the initiation of radiotherapy. 
Concurrent with radiation, weekly doses of cetuximab were 
administered at a dose of 250 mg/m2. Radiation doses varied 
between patients (5500 cGy/22#, n = 1, and 6600 cGy/30#, n = 
2). 
Results: The median age in our cohort was 85 years. All were 
male patients, with Karnofsky performance scores ≥ 60. Two 
patients were treated for primary SCC (T3N0M0 and T3N1M0) 
while the third patient was treated for recurrent disease. 
Notably, one patient presented with Waldenstrom’s 
macroglobulinemia. Treatment was well tolerated, and felt to 
be comparable to treatment with RT alone. One patient 
developed a Grade 2 acneiform skin reaction likely related to 
cetuximab. One patient developed an acute coronary syndrome 
(Grade 3), most likely unrelated to therapy. Two patients had a 
complete response to treatment. The first patient is in remission 
for 18 months and the second patient is in remission for 12 
months. The third patient completed CRT two months ago and is 
waiting for reassessment.  
Conclusions: Despite the frailty of our cohort, CRT was well 
tolerated and produced exceptional clinical outcomes. 
Limitations to this study include its small sample size and non-
randomization. This study will serve as the basis for a larger, 
prospective, randomized Phase II study which is now in 
